Astrazeneca (AZN) Non-Current Deffered Revenue (2018 - 2023)

Astrazeneca's Non-Current Deffered Revenue history runs 6 years deep, the most recent figure standing at $7.0 million for Q4 2023.

• In Q4 2023, Non-Current Deffered Revenue fell 50.0% year-over-year to $7.0 million; the TTM figure through Dec 2023 stood at $7.0 million (down 50.0% YoY), while the FY2023 annual figure was $7.0 million, down 50.0% from the prior year.
• Non-Current Deffered Revenue was $7.0 million for Q4 2023 at Astrazeneca, down from $14.0 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $50.0 million in Q4 2019 to a low of $7.0 million in Q4 2023.
• Historically, Non-Current Deffered Revenue has averaged $27.0 million across 5 years, with a median of $26.0 million in 2021.
• The sharpest annual moves came in 2020 and 2023: Non-Current Deffered Revenue retreated 24.0% in 2020, then sank 50.0% in 2023.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $50.0 million in 2019, then declined by 24.0% to $38.0 million in 2020, then tumbled by 31.58% to $26.0 million in 2021, then sank by 46.15% to $14.0 million in 2022, then tumbled by 50.0% to $7.0 million in 2023.
• The last three Non-Current Deffered Revenue figures came in at $7.0 million (Q4 2023), $14.0 million (Q4 2022), and $26.0 million (Q4 2021), per Business Quant data.